Xiaoyong Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyong Lv has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Pan Hao
Medical Imaging Center, LuHe Hospital, Capital Medical University, Beijing, China
2 shared publications - Ruiqiang Xin
Beijing Luhe Hospital, Capital Medical University, China
2 shared publications - Tong Zhu
Medical Imaging Center, LuHe Hospital, Capital Medical University, Beijing 101100, China
1 shared publication - Xu Na
Medical Imaging Center, LuHe Hospital, Capital Medical University, Beijing, China
1 shared publication - Yancui Li
Medical Imaging Center, LuHe Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2771
Stratified Analysis of Patients Within the PSA Gray Zone (4–10 ng/mL) and Its Clinical Application Value: Development of a Predictive Model for Clinically Significant Prostate Cancer Using Quantitative Indicators of PSA, ADC, and Relative T2 Value
Objective: Patients with prostate-specific antigen (PSA) levels in the 4–10 ng/mL gray zone present a diagnostic challenge, as PSA alone cannot reliably distinguish clinically significant prostate cancer (csPCa) from benign conditions or indolent disease, potentially leading to unnecessary biopsies or missed clinically significant disease. This study aimed to develop a risk prediction model for csPCa in this population using clinical indicators and magnetic resonance imaging (MRI) quantitative data, and to evaluate its potential value for risk stratification and as a supplementary tool for biopsy decision-making. Methods: We retrospectively included 210 patients with PSA levels in the 4–10 ng/mL range and confirmed pathological diagnoses, who were admitted to our hospital between January 2018 and June 2025. csPCa was defined as a Gleason score ≥ 7. Patients were stratified by pathological diagnosis (csPCa vs. non-csPCa) and randomly divided into training and internal validation sets in a 7:3 ratio. The following variables were collected for analysis: age, PSA, apparent diffusion coefficient (ADC), and relative T2 value. Univariate and multivariate logistic regression were used to identify independent predictors of csPCa. We constructed a prediction model and nomogram. The discriminating ability, calibration, and stability of the model were assessed using receiver operating characteristic (ROC) curves, calibration curves, and Bootstrap internal validation. Decision curve analysis (DCA) was performed to evaluate the model’s net benefit across clinically relevant threshold probabilities. Risk stratification was performed based on predicted probabilities. Results: Of the 210 patients, 50 had csPCa and 160 had non-csPCa lesions. Univariate regression showed associations between age, ADC value, and relative T2 value. Multivariate logistic regression identified age and relative T2 value as independent predictors in the final model. Internal validation using 1000 Bootstrap resampling with optimism correction yielded a corrected AUC of 0.698 (95% CI: 0.669–0.716), with a mean optimism of only 0.016, indicating minimal overfitting. The area under the curve (AUC) of the model was 0.720 in the training set and 0.711 in the validation set. The calibration curve for the training set demonstrated good agreement between predicted and observed probabilities. DCA showed net benefits across certain threshold probabilities. Risk stratification based on predicted probability showed csPCa detection rates of 14.7%, 28.3%, and 47.4% in low-, intermediate- and high-risk groups, respectively. Conclusions: The logistic binary classification model based on age and relative T2 value may assist in risk assessment for csPCa in PSA gray zone patients. However, its moderate discrimination suggests it should be used as a supplementary tool rather than a standalone diagnostic test. Risk stratification based on predicted probability may help identify different csPCa risk populations, but given the exploratory nature of this single-center retrospective study, multi-center, large-sample, and prospective studies are required for external validation and optimization before clinical implementation.
- 28 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2771
Open AccessStratified Analysis of Patients Within the PSA Gray Zone (4–10 ng/mL) and Its Clinical Application Value: Development of a Predictive Model for Clinically Significant Prostate Cancer Using Quantitative Indicators of PSA, ADC, and Relative T2 Value
Objective: Patients with prostate-specific antigen (PSA) levels in the 4–10 ng/mL gray zone present a diagnostic challenge, as PSA alone cannot reliably distinguish clinically significant prostate cancer (csPCa) from benign conditions or indolent disease, potentially leading to unnecessary biopsies or missed clinically significant disease. This study aimed to develop a risk prediction model for csPCa in this population using clinical indicators and magnetic resonance imaging (MRI) quantitative data, and to evaluate its potential value for risk stratification and as a supplementary tool for biopsy decision-making. Methods: We retrospectively included 210 patients with PSA levels in the 4–10 ng/mL range and confirmed pathological diagnoses, who were admitted to our hospital between January 2018 and June 2025. csPCa was defined as a Gleason score ≥ 7. Patients were stratified by pathological diagnosis (csPCa vs. non-csPCa) and randomly divided into training and internal validation sets in a 7:3 ratio. The following variables were collected for analysis: age, PSA, apparent diffusion coefficient (ADC), and relative T2 value. Univariate and multivariate logistic regression were used to identify independent predictors of csPCa. We constructed a prediction model and nomogram. The discriminating ability, calibration, and stability of the model were assessed using receiver operating characteristic (ROC) curves, calibration curves, and Bootstrap internal validation. Decision curve analysis (DCA) was performed to evaluate the model’s net benefit across clinically relevant threshold probabilities. Risk stratification was performed based on predicted probabilities. Results: Of the 210 patients, 50 had csPCa and 160 had non-csPCa lesions. Univariate regression showed associations between age, ADC value, and relative T2 value. Multivariate logistic regression identified age and relative T2 value as independent predictors in the final model. Internal validation using 1000 Bootstrap resampling with optimism correction yielded a corrected AUC of 0.698 (95% CI: 0.669–0.716), with a mean optimism of only 0.016, indicating minimal overfitting. The area under the curve (AUC) of the model was 0.720 in the training set and 0.711 in the validation set. The calibration curve for the training set demonstrated good agreement between predicted and observed probabilities. DCA showed net benefits across certain threshold probabilities. Risk stratification based on predicted probability showed csPCa detection rates of 14.7%, 28.3%, and 47.4% in low-, intermediate- and high-risk groups, respectively. Conclusions: The logistic binary classification model based on age and relative T2 value may assist in risk assessment for csPCa in PSA gray zone patients. However, its moderate discrimination suggests it should be used as a supplementary tool rather than a standalone diagnostic test. Risk stratification based on predicted probability may help identify different csPCa risk populations, but given the exploratory nature of this single-center retrospective study, multi-center, large-sample, and prospective studies are required for external validation and optimization before clinical implementation.
- Open Access
- 18 December 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-17
Developmental trends and knowledge frameworks in the application of radiomics in prostate cancer: a bibliometric analysis from 2000 to 2024
Background This research utilized the bibliometrics method to analyze the published literature related to prostate cancer (PCa) imaging. Furthermore, current knowledge and research hotspots of radiomics in PCa diagnosis and treatment were comprehensively reviewed, as well as progress and emerging trends in field were explored. Methods In this investigation, the relevant literature on radiomics, and PCa was retrieved from Web of Science Core Collection (WoSCC) databases from 2000 and 2024. Furthermore, a comprehensive bibliometric analysis was carried out using advanced tools like CiteSpace6.2, VOS viewer, and the 'bibliometrix' package of R software to visualize the annual distribution of publications across various aspects such as authors, countries, journals, institutions, and keywords. Results This analysis included 593 from 58 countries including China and the United States. Chinese Academy of Sciences and Frontiers in Oncology were the institutions and journals that publish the most relevant articles, -while Radiology journal had the greatest number of co-cited publications. Furthermore, 3,621 authors published on this topic, of which Madabhushi Anant and Stoyanova Radka had the highest contributions. Moreover, Lambin, P. had the most co-citations. In addition, the diagnostic characteristics of radiomics in PCa imaging and treatment strategies are the current research focal points. The establishment of multi-functional imaging techniques and independent factor models warrants future investigation. Conclusions In summary, this analysis revealed that the research on PCa imaging is developing vigorously, focusing on the diagnostic methods and intervention measures of imaging in PCa diagnosis and treatment. In the future, there is an urgent need for improved collaboration and communication among countries and institutions.
- 18 December 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-17
Open AccessDevelopmental trends and knowledge frameworks in the application of radiomics in prostate cancer: a bibliometric analysis from 2000 to 2024
Background This research utilized the bibliometrics method to analyze the published literature related to prostate cancer (PCa) imaging. Furthermore, current knowledge and research hotspots of radiomics in PCa diagnosis and treatment were comprehensively reviewed, as well as progress and emerging trends in field were explored. Methods In this investigation, the relevant literature on radiomics, and PCa was retrieved from Web of Science Core Collection (WoSCC) databases from 2000 and 2024. Furthermore, a comprehensive bibliometric analysis was carried out using advanced tools like CiteSpace6.2, VOS viewer, and the 'bibliometrix' package of R software to visualize the annual distribution of publications across various aspects such as authors, countries, journals, institutions, and keywords. Results This analysis included 593 from 58 countries including China and the United States. Chinese Academy of Sciences and Frontiers in Oncology were the institutions and journals that publish the most relevant articles, -while Radiology journal had the greatest number of co-cited publications. Furthermore, 3,621 authors published on this topic, of which Madabhushi Anant and Stoyanova Radka had the highest contributions. Moreover, Lambin, P. had the most co-citations. In addition, the diagnostic characteristics of radiomics in PCa imaging and treatment strategies are the current research focal points. The establishment of multi-functional imaging techniques and independent factor models warrants future investigation. Conclusions In summary, this analysis revealed that the research on PCa imaging is developing vigorously, focusing on the diagnostic methods and intervention measures of imaging in PCa diagnosis and treatment. In the future, there is an urgent need for improved collaboration and communication among countries and institutions.